Safety of reduced infusion times for nivolumab plus ipilimumab (N + I) and nivolumab alone (N) in advanced melanoma

Autor:	William H. Sharfman, W J Urba, A. Qureshi, T. C. Young, Salvador Martín-Algarra, Jedd D. Wolchok, Margaret K. Callahan, C. Horak, Craig L. Slingluff, Antoni Ribas, W. Hwu, J.B.A.G. Haanen, Shailender Bhatia, F.S. Hodi, Jason J. Luke
Rok vydání:	2016
Předmět:	Oncology medicine.medical_specialty business.industry Internal medicine medicine Ipilimumab Hematology Nivolumab business Advanced melanoma medicine.drug
Zdroj:	Annals of Oncology. 27:vi385
ISSN:	0923-7534
DOI:	10.1093/annonc/mdw379.20
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::f0ad7350d6b18ccf2be06220f0769a93 https://doi.org/10.1093/annonc/mdw379.20 Zobrazit plný text záznamu